Brian M. Mehling1, Louis Quartararo1, Marine Manvelyan*1, Paul Wang1 and Dong-Cheng Wu2,3
1Blue Horizon International, LLC, 214 State Street, Hackensack, New Jersey 07601, USA
2Biochemistry Institute, Wuhan University, Hubei 430071, P.R. China
3Department of Stem Cells, Wuhan Hongqiao Brain Hospital, Wuhan, Hubei 430071, P.R. China
*Corresponding author: Marine Manvelyan, Blue Horizon International, LLC, 214
State Street, Hackensack, New Jersey 07601, USA, Tel: 201342-7662; E-mail:
mmanvelyan@bluehorizonhospital.com
Received July 10, 2015; Accepted August 12, 2015; Published August 14, 2015
Citation: Mehling BM, Quartararo L, Manvelyan M, Wang P, Wu DC (2015)
Evaluation of Immune response to Intravenously Administered Human Cord Blood
Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation. J Stem
Cell Res Ther 5: 297. doi:10.4172/2157-7633.1000297
Copyright: © 2015 Mehling BM, et al This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Abstract
Objective: Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) in general represent a
valuable tool for therapy of symptoms related to chronic inflammatory diseases. Blue Horizon Stem Cell Therapy
Program is a leading provider of adult and children’s stem cell therapies. Uniquely we have safely and efficiently
treated over 600 patients with documenting each procedure.
Methods: The purpose of our study is primarily to monitor the immune response in order to validate the safety of
intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs), and secondly, to evaluate effects on
biomarkers associated with chronic inflammation. Twenty patients were treated for conditions associated with chronic
inflammation and for the purpose of anti-aging. They have been given one intravenous infusion of UC-MSCs.
Results: Our study of blood test markers of 20 patients with chronic inflammation before and within three months
after MSCs treatment demonstrates that there are no significant changes and MSCs treatment was safe for the
patients. Analysis of different indicators of chronic inflammation and aging included in initial, 24-hours, two weeks and
three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions.
Moreover, data from follow-up protocols demonstrate significant improvement in energy level, hair, nail growth and
skin conditions.
Conclusion: Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms
related to chronic inflammation. Further close monitoring and inclusion of more patients are necessary to fully
characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.
Leave a Reply